Charles Schwab’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$232M Buy
3,439,164
+263,865
+8% +$17.6M 0.03% 411
2026
Q1
$199M Buy
3,175,299
+95,988
+3% +$6.68M 0.03% 425
2025
Q4
$204M Sell
3,079,311
-103,822
-3% -$6.71M 0.03% 402
2025
Q3
$214M Buy
3,183,133
+109,867
+4% +$8.69M 0.03% 392
2025
Q2
$268M Buy
3,073,266
+95,710
+3% +$7.5M 0.05% 318
2025
Q1
$203M Buy
2,977,556
+152,350
+5% +$12.4M 0.04% 376
2024
Q4
$220M Buy
2,825,206
+91,051
+3% +$6.74M 0.04% 359
2024
Q3
$183M Buy
2,734,155
+288,381
+12% +$23.7M 0.04% 398
2024
Q2
$277M Buy
2,445,774
+115,472
+5% +$14.6M 0.05% 292
2024
Q1
$323M Buy
2,330,302
+88,601
+4% +$11.1M 0.07% 233
2023
Q4
$278M Buy
2,241,701
+80,740
+4% +$8.25M 0.07% 246
2023
Q3
$202M Buy
2,160,961
+28,621
+1% +$3.23M 0.06% 300
2023
Q2
$274M Buy
2,132,340
+24,599
+1% +$2.98M 0.08% 215
2023
Q1
$245M Buy
2,107,741
+34,199
+2% +$3.83M 0.07% 227
2022
Q4
$235M Buy
2,073,542
+38,958
+2% +$4.28M 0.08% 239
2022
Q3
$164M Buy
2,034,584
+46,651
+2% +$3.95M 0.06% 299
2022
Q2
$148M Buy
1,987,933
+62,957
+3% +$5.75M 0.05% 329
2022
Q1
$246M Buy
1,924,976
+53,352
+3% +$5.84M 0.07% 249
2021
Q4
$251M Buy
1,871,624
+47,772
+3% +$6.86M 0.07% 236
2021
Q3
$249M Buy
1,823,852
+33,924
+2% +$4.28M 0.08% 215
2021
Q2
$191M Buy
1,789,928
+69,452
+4% +$6.67M 0.06% 276
2021
Q1
$155M Buy
1,720,476
+25,904
+2% +$2.43M 0.06% 305
2020
Q4
$157M Sell
1,694,572
-54,176
-3% -$4.84M 0.06% 282
2020
Q3
$180M Buy
1,748,748
+110,068
+7% +$11.5M 0.08% 213
2020
Q2
$166M Buy
1,638,680
+662,124
+68% +$59.2M 0.08% 225
2020
Q1
$65.7M Sell
976,556
-12,040
-1% -$749K 0.04% 420
2019
Q4
$54.1M Sell
988,596
-10,632
-1% -$504K 0.03% 577
2019
Q3
$37.3M Sell
999,228
-756,756
-43% -$29.4M 0.02% 746
2019
Q2
$65.8M Buy
1,755,984
+53,792
+3% +$1.69M 0.04% 441
2019
Q1
$50.7M Buy
1,702,192
+282,280
+20% +$9.92M 0.03% 537
2018
Q4
$42.5M Buy
1,419,912
+67,204
+5% +$2.13M 0.03% 529
2018
Q3
$48.4M Buy
1,352,708
+78,524
+6% +$2.43M 0.03% 546
2018
Q2
$30.3M Buy
1,274,184
+93,156
+8% +$1.98M 0.02% 777
2018
Q1
$21.9M Buy
1,181,028
+129,972
+12% +$1.92M 0.02% 939
2017
Q4
$15.1M Sell
1,051,056
-9,020
-0.9% -$117K 0.01% 1189
2017
Q3
$13M Buy
1,060,076
+32,684
+3% +$578K 0.01% 1221
2017
Q2
$18.8M Buy
1,027,392
+118,432
+13% +$2.19M 0.02% 891
2017
Q1
$19.3M Buy
908,960
+27,252
+3% +$532K 0.02% 851
2016
Q4
$13.2M Buy
881,708
+54,612
+7% +$967K 0.01% 1064
2016
Q3
$18.1M Buy
827,096
+35,240
+4% +$784K 0.02% 750
2016
Q2
$15.7M Buy
791,856
+65,192
+9% +$1.11M 0.02% 782
2016
Q1
$12.3M Buy
726,664
+27,084
+4% +$452K 0.02% 907
2015
Q4
$14.3M Buy
699,580
+58,948
+9% +$1.23M 0.02% 793
2015
Q3
$13.8M Buy
640,632
+77,976
+14% +$1.74M 0.02% 761
2015
Q2
$11.3M Sell
562,656
-404,252
-42% -$7.1M 0.02% 942
2015
Q1
$15.1M Buy
966,908
+167,180
+21% +$2.53M 0.02% 727
2014
Q4
$11M Buy
799,728
+10,028
+1% +$123K 0.02% 819
2014
Q3
$7.9M Buy
789,700
+24,688
+3% +$252K 0.01% 1007
2014
Q2
$7.59M Buy
765,012
+11,672
+2% +$103K 0.01% 1051
2014
Q1
$7.79M Buy
753,340
+43,004
+6% +$444K 0.01% 989
2013
Q4
$6.29M Buy
710,336
+42,524
+6% +$337K 0.01% 1073
2013
Q3
$4.7M Buy
667,812
+12,344
+2% +$78.2K 0.01% 1231
2013
Q2
$3.74M Buy
+655,468
New +$3.14M 0.01% 1300

Other funds holding DXCM

Charles Schwab's DXCM Position: Q2 2026 in Review

Charles Schwab increased its DexCom (DXCM) stake by 8.3% in Q2 2026, buying an estimated $17.6M and bringing the position to 3,439,164 shares worth $232M. The position accounts for 0.03% of the portfolio, ranked #411.

Charles Schwab first reported a position in DXCM in Q2 2013 and has held it in 53 quarters since. The position peaked at $323M in Q1 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Charles Schwab held 3,439,164 shares of DexCom worth $232M as of Q2 2026.
  • Charles Schwab bought 263,865 DexCom shares in Q2 2026, an estimated $17.6M.
  • DexCom made up 0.03% of Charles Schwab's portfolio in Q2 2026, its #411 holding.
  • Charles Schwab first reported a position in DexCom in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's DexCom position peaked at $323M in Q1 2024.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.